511 related articles for article (PubMed ID: 20628435)
1. Evaluation of the endothelin receptor antagonists ambrisentan, darusentan, bosentan, and sitaxsentan as substrates and inhibitors of hepatobiliary transporters in sandwich-cultured human hepatocytes.
Hartman JC; Brouwer K; Mandagere A; Melvin L; Gorczynski R
Can J Physiol Pharmacol; 2010 Jun; 88(6):682-91. PubMed ID: 20628435
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of the endothelin receptor antagonists ambrisentan, bosentan, macitentan, and sitaxsentan as hepatobiliary transporter inhibitors and substrates in sandwich-cultured human hepatocytes.
Lepist EI; Gillies H; Smith W; Hao J; Hubert C; St Claire RL; Brouwer KR; Ray AS
PLoS One; 2014; 9(1):e87548. PubMed ID: 24498134
[TBL] [Abstract][Full Text] [Related]
3. Fasiglifam (TAK-875) Inhibits Hepatobiliary Transporters: A Possible Factor Contributing to Fasiglifam-Induced Liver Injury.
Li X; Zhong K; Guo Z; Zhong D; Chen X
Drug Metab Dispos; 2015 Nov; 43(11):1751-9. PubMed ID: 26276582
[TBL] [Abstract][Full Text] [Related]
4. Differential inhibition of rat and human Na+-dependent taurocholate cotransporting polypeptide (NTCP/SLC10A1)by bosentan: a mechanism for species differences in hepatotoxicity.
Leslie EM; Watkins PB; Kim RB; Brouwer KL
J Pharmacol Exp Ther; 2007 Jun; 321(3):1170-8. PubMed ID: 17374746
[TBL] [Abstract][Full Text] [Related]
5. Effects of bosentan, an endothelin receptor antagonist, on bile salt export pump and multidrug resistance-associated protein 2.
Mano Y; Usui T; Kamimura H
Biopharm Drug Dispos; 2007 Jan; 28(1):13-8. PubMed ID: 17061295
[TBL] [Abstract][Full Text] [Related]
6. Hepatocellular organic anion-transporting polypeptides (OATPs) and multidrug resistance-associated protein 2 (MRP2) are inhibited by silibinin.
Wlcek K; Koller F; Ferenci P; Stieger B
Drug Metab Dispos; 2013 Aug; 41(8):1522-8. PubMed ID: 23695864
[TBL] [Abstract][Full Text] [Related]
7. Ritonavir, saquinavir, and efavirenz, but not nevirapine, inhibit bile acid transport in human and rat hepatocytes.
McRae MP; Lowe CM; Tian X; Bourdet DL; Ho RH; Leake BF; Kim RB; Brouwer KL; Kashuba AD
J Pharmacol Exp Ther; 2006 Sep; 318(3):1068-75. PubMed ID: 16720753
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of bile acid transport across Na+/taurocholate cotransporting polypeptide (SLC10A1) and bile salt export pump (ABCB 11)-coexpressing LLC-PK1 cells by cholestasis-inducing drugs.
Mita S; Suzuki H; Akita H; Hayashi H; Onuki R; Hofmann AF; Sugiyama Y
Drug Metab Dispos; 2006 Sep; 34(9):1575-81. PubMed ID: 16760228
[TBL] [Abstract][Full Text] [Related]
9. Optimized Hepatocyte-Like Cells with Functional Drug Transporters Directly-Reprogrammed from Mouse Fibroblasts and their Potential in Drug Disposition and Toxicology.
Wu ZT; Yao D; Ji SY; Ni X; Gao YM; Hui LJ; Pan GY
Cell Physiol Biochem; 2016; 38(5):1815-30. PubMed ID: 27160211
[TBL] [Abstract][Full Text] [Related]
10. Determination of OATP-, NTCP- and OCT-mediated substrate uptake activities in individual and pooled batches of cryopreserved human hepatocytes.
De Bruyn T; Ye ZW; Peeters A; Sahi J; Baes M; Augustijns PF; Annaert PP
Eur J Pharm Sci; 2011 Jul; 43(4):297-307. PubMed ID: 21605667
[TBL] [Abstract][Full Text] [Related]
11. Regulation of human hepatic drug transporter activity and expression by diesel exhaust particle extract.
Le Vee M; Jouan E; Stieger B; Lecureur V; Fardel O
PLoS One; 2015; 10(3):e0121232. PubMed ID: 25803276
[TBL] [Abstract][Full Text] [Related]
12. Macitentan does not interfere with hepatic bile salt transport.
Treiber A; Äänismaa P; de Kanter R; Delahaye S; Treher M; Hess P; Sidharta P
J Pharmacol Exp Ther; 2014 Jul; 350(1):130-43. PubMed ID: 24769543
[TBL] [Abstract][Full Text] [Related]
13. The endothelin antagonist bosentan inhibits the canalicular bile salt export pump: a potential mechanism for hepatic adverse reactions.
Fattinger K; Funk C; Pantze M; Weber C; Reichen J; Stieger B; Meier PJ
Clin Pharmacol Ther; 2001 Apr; 69(4):223-31. PubMed ID: 11309550
[TBL] [Abstract][Full Text] [Related]
14. Influence of sildenafil and tadalafil on the enzyme- and transporter-inducing effects of bosentan and ambrisentan in LS180 cells.
Weiss J; Theile D; Spalwisz A; Burhenne J; Riedel KD; Haefeli WE
Biochem Pharmacol; 2013 Jan; 85(2):265-73. PubMed ID: 23219525
[TBL] [Abstract][Full Text] [Related]
15. Obstructive cholestasis induces TNF-alpha- and IL-1 -mediated periportal downregulation of Bsep and zonal regulation of Ntcp, Oatp1a4, and Oatp1b2.
Donner MG; Schumacher S; Warskulat U; Heinemann J; Häussinger D
Am J Physiol Gastrointest Liver Physiol; 2007 Dec; 293(6):G1134-46. PubMed ID: 17916651
[TBL] [Abstract][Full Text] [Related]
16. The role of the sodium-taurocholate cotransporting polypeptide (NTCP) and of the bile salt export pump (BSEP) in physiology and pathophysiology of bile formation.
Stieger B
Handb Exp Pharmacol; 2011; (201):205-59. PubMed ID: 21103971
[TBL] [Abstract][Full Text] [Related]
17. Drug metabolizing enzyme and transporter protein profiles of hepatocytes derived from human embryonic and induced pluripotent stem cells.
Ulvestad M; Nordell P; Asplund A; Rehnström M; Jacobsson S; Holmgren G; Davidson L; Brolén G; Edsbagge J; Björquist P; Küppers-Munther B; Andersson TB
Biochem Pharmacol; 2013 Sep; 86(5):691-702. PubMed ID: 23856292
[TBL] [Abstract][Full Text] [Related]
18. Multiple compound-related adverse properties contribute to liver injury caused by endothelin receptor antagonists.
Kenna JG; Stahl SH; Eakins JA; Foster AJ; Andersson LC; Bergare J; Billger M; Elebring M; Elmore CS; Thompson RA
J Pharmacol Exp Ther; 2015 Feb; 352(2):281-90. PubMed ID: 25467130
[TBL] [Abstract][Full Text] [Related]
19. Glutamine attenuates obstructive cholestasis in rats via farnesoid X receptor-mediated regulation of Bsep and Mrp2.
Liu B; Li Y; Ji H; Lu H; Li H; Shi Y
Can J Physiol Pharmacol; 2017 Feb; 95(2):215-223. PubMed ID: 28051334
[TBL] [Abstract][Full Text] [Related]
20. Multiple human isoforms of drug transporters contribute to the hepatic and renal transport of olmesartan, a selective antagonist of the angiotensin II AT1-receptor.
Yamada A; Maeda K; Kamiyama E; Sugiyama D; Kondo T; Shiroyanagi Y; Nakazawa H; Okano T; Adachi M; Schuetz JD; Adachi Y; Hu Z; Kusuhara H; Sugiyama Y
Drug Metab Dispos; 2007 Dec; 35(12):2166-76. PubMed ID: 17823233
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
